IL2 and neoplasm: The stronger anti-tumor effects observed for Alb-IL2 compared to IL-2 could be attributed to its enhanced half-life which extends contact with IL-2R + lymphocytes, such as T cells, and ultimately potentiates T cell immunity [16].